MGI Tech Unveils Next-Generation Automation Portfolio at SLAS Europe 2025 in Germany

May 22, 2025 03:38 AM BST | By Cision
 MGI Tech Unveils Next-Generation Automation Portfolio at SLAS Europe 2025 in Germany
Image source: Kalkine Media

HAMBURG, Germany, May 22, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences,  is proud to unveil its latest innovation, PrepALL, a flexible liquid handling system, along with the latest version of the Smart8 at SLAS Europe 2025, taking place from May 20–22 in Hamburg. Featuring advanced robotics, AI integration, and modular platforms, MGI's automation portfolio addresses critical challenges in genomics, drug discovery, synthetic biology, and molecular diagnostics—empowering labs of all sizes to scale research efficiently.

PrepALL: Compact, Affordable Automation for Flexible Pipetting

The PrepALL Flexible Liquid Handling Platform simplifies complex laboratory tasks while maintaining enterprise-level performance—without the high costs typically associated with traditional systems. Compact yet powerful, PrepALL is ideal for laboratories adopting automation for the first time or scaling existing research capacity.

PrepALL
PrepALL

Key Features Include:

  • Space-saving design: Occupies just 0.7 m², with 16 SBS deck positions (expandable to 41).
  • High-precision pipetting: 8 independent channels support 0.5–1200 µL volumes with CVs (coefficients of variation) of less than 3% (1–50 µL) and <1% (50–1200 µL). It supports pLLD/cLLD, liquid level tracking, and anti-dripping, so that it reduces dead volume and improves pipetting accuracy.
  • Plug-and-play setup and easy to use: Integrated with a visual system, it can achieve automatic consumables identification and automatic position calibration
  • Full traceability: Built-in sensors and data logging ensure reproducibility and consistency.

Leveraging advanced vision-based AI, PrepALL delivers high-precision performance in critical applications such as nucleic acid extraction, plasmid construction, sample preparation, and NGS library prep. Designed for global accessibility, it addresses cost and complexity barriers with a scalable, modular design and open APIs. Ideal for both entry-level and high-throughput environments, PrepALL empowers smaller labs to scale without costly infrastructure overhauls.

"PrepALL represents a major leap in lab automation, giving labs of all sizes the ability to streamline complex workflows with unmatched affordability and reliability. It's a bold step in our mission to democratize cutting-edge tools and accelerate scientific discovery worldwide." said Dr. Christian Zimmerman, VP of Sales at MGI Europe and Africa.

Scalable Automation Ecosystem for Every Lab

MGI's automation portfolio is among the most versatile in the industry, designed to meet diverse laboratory needs while ensuring scalability and ease of use. At SLAS Europe 2025, MGI also presents Smart 8, a globally recognized solution launched in 2022. Smart 8 features eight-channel pipetting, and smart gripper technology. The new enhancement introduces AI-optimized pipetting for up to 20% faster cycle times, including nucleic acid extraction, microbial screening, and library preparation. This update ensures higher reproducibility and efficiency, making the Smart 8 an ideal partner for labs seeking reliable automation while remaining cost-effective.

The enhanced capabilities of the Smart 8 will cater to academic institutions, biotech startups, and clinical labs, offering a competitive edge in high-throughput research. By reducing manual intervention, the system accelerates time-to-results, enabling researchers to focus on data analysis and discovery.

Affordable, Scalable, Smart: The MGI Automation Edge

MGI stands out in the lab automation market by prioritizing cost-effectiveness, scalability, and global accessibility. Designed to democratize advanced technology, MGI empowers researchers across diverse fields—from precision medicine to agriculture—regardless of budget constraints.

MGI provides a comprehensive portfolio that covers the entire workflow, from sample extraction and preparation to sequencing and data analysis. This all-in-one solution enhance chances to meet customers' diversified demand under one system and brand and ensures compatibility among various systems, simplifying the overall experimental workflow.

These advantages have positioned MGI as a trusted partner in more than 100 countries, accelerating breakthroughs in genomics, synthetic biology, and beyond. During global health crises, systems like the Platforms like the MGISP-960 and MGISTP-7000 have processed millions of samples, demonstrating MGI's ability to deliver robust solutions under pressure.

MGI invites researchers, lab managers, and industry professionals to explore its latest automation solutions at SLAS Europe 2025. Visit MGI's booth#516 to see the enhanced innovations in action.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

AI on the Rise: A Look at Top AI Companies and Their Stocks

Send OTP Resend OTP in 30s
Verify OTP

Sponsored Articles


Investing Ideas

Previous Next

Top FTSE Listed Companies